News

Open

Advertisement

News

1-20 of 3216 results
1 2 3 4 5 Next »

Dilated Aortic Root Associated with Higher Rates of Aortic Dissection at a Smaller Diameter: IRAD Registry

May 09, 2022 by
Sukhdeep Bhogal, CRTonline.org

Patients with modest dilation in the aortic root (AR) had acute type A aortic dissections (ATAD) at a significantly smaller diameter compared to patients with modestly dilated ascending aorta (AA), according to registry data

Any Level of Coronary Artery Calcium Means Increased CV Risk in Young Adults, Pooled Analysis Shows

May 09, 2022 by
Amer Aladin and Jason Wermers, CRTonline.org

Any degree of coronary artery calcium (CAC) detected by computed tomography (CT) imaging in asymptomatic adults between the ages of 30 and 45 is associated with higher cardiovascular risk, according to a pooled analysis of three studies.

CMR May Help Assess Risk for Coronary Artery Compression Prior to TPVi

May 02, 2022 by
Nathan Gray, CRTonline.org

Cardiac magnetic resonance (CMR) can be a “useful tool” in assessing risk for coronary artery (CA) compression in patients undergoing transcatheter pulmonary valve implantation (TPVi) for treatment of dysfunctional RV-PA conduits, according to a new multi-center retrospective analysis.

Aspirin-Free Anticoagulant Regimens Post-LAAO with Watchman Carry Less Risk – Large-Scale Registry

May 02, 2022 by
Natalie Morrison, CRTonline.org

Patients undergoing left atrial appendage occlusion (LAAO) with the Watchman device had lower risk of adverse outcomes when discharged on warfarin or direct oral anticoagulant (DOAC) without concomitant aspirin – a step away from the U.S. approved regimen.

Real-World Watchman LAAO Patients at Higher Risk of Death vs. Pivotal Trials’ Populations – Registry Study

May 02, 2022 by
Natalie Morrison, CRTonline.org

Atrial fibrillation (AF) patients in real-world clinical practice who underwent left atrial appendage occlusion (LAAO) with the Watchman device were at higher risk of dying than patients in the two pivotal trials used for its U.S. Food and Drug Administration (FDA) approval.

Elevated Mitral Pressure Gradient Associated with 5-Year Adverse Outcome in Degenerative MR Patients

May 02, 2022 by
Nathan Gray, CRTonline.org

Elevated postprocedural mitral valve pressure gradient (MPG) is an independent predictor of adverse clinical and functional outcomes in patients with degenerative mitral regurgitation (DMR) but not in those with functional mitral regurgitation (FMR), a new long-term outcomes study reports.

FDA Approves Mavacamten for Obstructive HCM

Apr 29, 2022 by
CRTonline.org

The U.S. Food and Drug Administration (FDA) approved mavacamten as a treatment for adults with New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (HCM), according to the drug’s manufacturer, Bristol Myers Squibb.

FDA Announces Class I Recall of Medtronic’s Harmony Catheter

Apr 27, 2022 by
CRTonline.org

Medtronic’s announced recall of the Harmony delivery catheter for its Harmony Transcatheter Pulmonary Valve (TPV) System has been identified as a Class I recall, the most serious type, according to the U.S. Food and Drug Administration (FDA).

KDIGO Guidance Indicates 10% of At-Risk Nondialysis CKD Patients for Anti-Hypertensive Therapy, South Korean Study Finds

Apr 25, 2022 by
Natalie Morrison, CRTonline.org

New international guidance means more intensive blood pressure-lowering treatment is indicated for more than 10% of patients with chronic kidney disease (CKD), who are otherwise at high risk of cardiovascular events, according to a new South Korean database study.

Icosapent Ethyl Significantly Reduced Ischemic Events in REDUCE-IT Patients With Prior MI: Post Hoc Analysis

Apr 25, 2022 by
Nathan Gray, CRTonline.org

Icosapent ethyl (IPE) significantly reduced ischemic events in patients with prior myocardial infarction (MI) in the Phase IIIb REDUCE-IT trial, including cardiovascular deaths.

Real-World Data Link Septal Myectomy with Lower Long-Term Mortality in Obstructive HCM

Apr 25, 2022 by
Nathan Gray, CRTonline.org

Alcohol septal ablation (ASA) is associated with greater all-cause long-term mortality than surgical septal myectomy in patients with obstructive hypertrophic cardiomyopathy (HCM), new real-world data suggest.

US HF Hospitalization Rising in Young Adults, Particularly Black People with Low Income: 15-Year Analysis

Apr 25, 2022 by
Natalie Morrison, CRTonline.org

Heart failure (HF) hospitalization has increased among young adults in the U.S. since 2013, and almost half of these patients are Black and from homes in the lowest quartile of national household income, according to a new 15-year analysis.

CHD Patients’ Lifestyle Physical Activity Trajectories Should Become Routine Clinical Practice Focus: Longitudinal Study Researchers

Apr 25, 2022 by
Natalie Morrison, CRTonline.org

Attention to patients’ physical activity trajectories should become routine in coronary heart disease (CHD) clinical practice, said the researchers of a new longitudinal study that highlights the potential benefit of preserved or increased activity.

SCAI Releases Position Statement on CLTI Care

Apr 25, 2022 by
Sukhdeep Bhogal, CRTonline.org

In an effort to improve outcomes in individuals with chronic limb-threatening ischemia (CLTI), a multispecialty societal group convened to develop a position statement outlining competencies for endovascular specialists providing CLTI care.

Patients with ACS Complicated by Cardiogenic Shock Show Comparable Outcomes Regardless of Hospital Experience – Australian Registry

Apr 18, 2022 by
Amer Aladin and Jason Wermers, CRTonline.org

Patients who present with acute coronary syndrome (ACS) complicated by cardiogenic shock (CS) show comparable outcomes regardless of the treating hospital’s percutaneous coronary intervention (PCI) CS volume experience or whether cardiac surgery is available, an Australian multicenter registry shows.

FORT CTO: Transradial, Transfemoral Approaches Show Similar Procedural Success

Apr 18, 2022 by
Giorgio A. Medranda, CRTonline.org

A transradial access (TRA) approach was found to be non-inferior to a transfemoral access (TFA) approach in chronic total occlusion (CTO) but did demonstrate fewer access-site related complications, according to the Femoral or Radial Approach in the Treatment of Coronary Chronic Total Occlusion (FORT CTO) trial.

Premature DAPT Cessation Post-DES Implantation Associated With Higher MACE Rates: ADAPT-DES Registry

Apr 18, 2022 by
Sukhdeep Bhogal, MD, CRTonline.org

Premature discontinuation of dual antiplatelet therapy (DAPT) was associated with a markedly increased risk of major adverse cardiac events (MACE), which occurred in approximately 1 in 6 patients following drug-eluting stent (DES) implantation, according to new results from a registry study.

ARIC Analysis: Abnormal Left Atrial Measures Predict Higher HF Risk, Regardless of LV Function

Apr 18, 2022 by
Mohit Pahuja, CRTonline.org

In a large cohort of older adults free of prevalent heart failure (HF), abnormal measures of left atrial (LA) structure and function are associated with increased risk of incident HF or death at long-term follow-up, regardless of measures of left ventricular function and NT-proBNP, according to a new analysis of the ARIC study population.

Pilot Trial Backs Transluminal Pulmonary Angioplasty for Rare Takayasu Arteritis–Associated Pulmonary Hypertension

Apr 11, 2022 by
Nathan Gray, CRTonline.org

The use of percutaneous transluminal pulmonary angioplasty (PTPA) may improve survival in patients with Takayasu arteritis–associated pulmonary hypertension (TA-PH), according to the outcomes of a new pilot study.

Analysis: FREEDOM Score ‘Helpful’ for MACE Prediction in PCI, Moderate for CABG

Apr 11, 2022 by
Nathan Gray, CRTonline.org

The FREEDOM score performs well in predicting 5-year major adverse cardiovascular events (MACE) for percutaneous coronary intervention (PCI) but has only moderate discrimination and calibration for coronary artery bypass grafting (CABG), according to a new external validation analysis, which also identified heterogeneity of treatment benefit.

1-20 of 3216 results
1 2 3 4 5 Next »

CRTonline on Facebook

CRT Meeting

CRTonline on Twitter

Tweets by CRT_meeting

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

CRTonline on Facebook

CRTonline on Twitter

Explore the Site

Stay Connected